<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565861</url>
  </required_header>
  <id_info>
    <org_study_id>NP10679-001</org_study_id>
    <nct_id>NCT03565861</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized , Double Blind, Single Ascending Dose Study to Investigate Safety, Tolerability and PK of NP10679 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurop Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurop Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered
      intravenously in escalating dose levels in comparison to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NP10679 is a pH dependent inhibitor of the GluN2B subtype of the NMDA receptor. Compounds of
      this drug class are hypothesized to be beneficial in a number of central nervous system
      disorders, including brain ischemia associated with subarachnoid hemorrhage, severe pain,
      major depression and substance abuse disorders. This study uses a double blind, adaptive
      design approach to evaluate the safety, tolerability and pharmacokinetics of a single dose of
      NP10679 when delivered intravenously in up to six escalating dose levels in comparison to
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Adaptive design of placebo and up to six escalating doses of NP10679</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>8 days</time_frame>
    <description>Observed side effects and alteration in laboratory values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of parent drug</measure>
    <time_frame>4 days</time_frame>
    <description>Cmax after administration.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intravenous 30 minute infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 5 mg intravenous infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 15 mg intravenous infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 50 mg intravenous infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 100 mg intravenous infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 200 mg intravenous infusion on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP10679 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP10679 300 mg intravenous infusion on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous vehicle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP10679</intervention_name>
    <description>NP10679</description>
    <arm_group_label>NP10679 100 mg</arm_group_label>
    <arm_group_label>NP10679 15 mg</arm_group_label>
    <arm_group_label>NP10679 200 mg</arm_group_label>
    <arm_group_label>NP10679 300 mg</arm_group_label>
    <arm_group_label>NP10679 5 mg</arm_group_label>
    <arm_group_label>NP10679 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 18 to 55 years

          -  Ability to understand the requirements of the study, provide written informed consent,
             abide by the study restrictions, and agree to return for the required assessments.

          -  If of child bearing potential (both men and women) must agree to use 2 forms of
             contraceptive methods for the duration of study.

        Exclusion Criteria:

          -  Clinical laboratory values greater than or equal to 2 times the upper limit of normal.

          -  Recent history (within 2 yrs) or current tobacco use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zaczek, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Neurop Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo DePetrillo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaron CPC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaron CPC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

